Pharma to benefit from demographic tailwind
Pharma to benefit from demographic tailwind
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
While investors remain concerned about inflationary pressures, Hugh Selby-Smith, Co-CIO at Talaria Capital maintains that the bulk of investor assets are exposed to sectors that will continue to do well. Talaria focuses on international opportunities. Hugh acknowledges that there's market nervousness about valuation, although still high historically and concentrated around a few top stocks, with Tesla doing much of the driving up of the index. Hugh says if investors feel inflation is more permanent, then there is still time to make that change to value, other sectors, other regions and return type. Hugh is seeing continued opportunity in pharma, which he says has been a long term stable growth sector with a huge demographic tailwind. Specifically, Hugh likes Johnson and Johnson (JNJ), which he says has a good pipeline of new drugs due to come to market. And he says the company's consumer devices business will benefit from the big build up in elective surgery. Overall, he says it's trading at a discount to book value.